Specialists in a field we helped define.
For life sciences organizations developing important therapies, evidence arrives too slowly and is too incomplete to influence important decisions.
Data sources are fragmented, incomplete, and frequently unreliable. Evidence generation workflow is highly manual, expensive, and lengthy. These problems are pervasive throughout the drug lifecycle. High-validity evidence generation requires data that meet a defined quality standard, and meeting that standard requires measuring and optimizing accuracy, completeness, and traceability.
We started working on this problem with Dan Riskin's Congressional testimony on the 21st Century Cures Initiative, which established the regulatory pathway for real-world evidence. Subsequently, we were funded by the NIH, NSF, and FDA based on exceptional science which is foundational to our solutions.
The Verantos pharmacoepidemiology stack transforms fragmented real-world data into high-validity evidence, and automates and accelerates traditionally manual research workflows. A scalable and reusable AI foundation supports R&D, clinical development, commercial, regulatory, and safety use cases.
